Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sits in the top decile of US sponsors by registered trial count (#69 of 15,742 sponsors by registered trial count).

523 total trials 69 currently recruiting 301 completed early-phase tilt top decile by trial count

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: 523 sponsored US clinical trials, 69 recruiting.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sponsors 523 registered US clinical trials on ClinicalTrials.gov, 69 of them currently recruiting, and 301 completed. 5 of these trials are in Phase 3-4 (later-stage) and 395 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 17 trials.

Top-decile sponsor footprint

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ranks in the top decile of sponsors by registered trial count (#69 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 20/100

301 of 415 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (72.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

523 total, page 9 of 11

COMPLETED Phase 2

Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT00425477
COMPLETED

Prospective Assessment of Symptoms and Quality of Life in Rectal Cancer Patients Receiving Chemo-Radiotherapy

NCT00414232
COMPLETED Phase 1

Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma

NCT00401024
TERMINATED Phase 2

Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy

NCT00390364
TERMINATED Phase 1

Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies

NCT00356928
COMPLETED Phase 2

Adjuvant GVAX Vaccine Therapy in Patients With Pancreatic Cancer

NCT00389610
COMPLETED Phase 2

Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment

NCT00673569
COMPLETED Phase 2

Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for the Treatment of HER-2/Neu-Overexpressing Metastatic Breast Cancer

NCT00399529
COMPLETED Phase 2

Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI

NCT00363649
COMPLETED Phase 1

Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer

NCT00311623
COMPLETED Phase 1

Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer

NCT00348595
COMPLETED

Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma

NCT00416312
TERMINATED Phase 1

One Time Injection of Bacteria to Treat Solid Tumors That Have Not Responded to Standard Therapy

NCT00358397
COMPLETED NA

Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With ABC

NCT00321048
COMPLETED

Transitoriness in Cancer Patients, Psychosocial Issues in Cancer Care

NCT00364078
COMPLETED NA

Study of Robotic Template Guidance for Needle Placement in Transperineal Prostate Brachytherapy

NCT00381966
COMPLETED Phase 2

Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer

NCT00354640
COMPLETED

Melanoma Biomarker Study

NCT00348088
COMPLETED

Effect of Surgery, Radiation Therapy, Chemotherapy, and Hormone Therapy on Biomarkers in Women With Stage I, Stage II, Stage III Breast Cancer, or Ductal Carcinoma In Situ That Can Be Removed By Surgery

NCT00373191
COMPLETED Phase 2

Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma

NCT00369681
TERMINATED NA

Iodine I 131 in Treating Patients With Thyroid Cancer

NCT00416949
COMPLETED Phase 2

ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)

NCT00313560
COMPLETED Phase 2

Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast Cancer

NCT00334542
COMPLETED Phase 2

Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM

NCT00262730
TERMINATED NA

Identification of a Screening Tool and Treatment of Lymphedema Secondary to the Management of Breast Cancer Study

NCT00282529
TERMINATED Phase 3

Modafinil in Opioid Induced Sedation

NCT00267332
COMPLETED Phase 2

Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer

NCT00305760
COMPLETED Phase 2

Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene

NCT00303927
COMPLETED Phase 1

Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer

NCT00290732
COMPLETED Phase 1

Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders

NCT00293410
COMPLETED Phase 1

Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma

NCT00134082
TERMINATED NA

Infrared Thermography in Finding Skin Lesions in Patients With Kaposi's Sarcoma

NCT00265902
TERMINATED Phase 1

Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia

NCT00245115
TERMINATED Phase 2

Individualized Drug Treatment for Treating Patients With Pancreatic Cancer

NCT00276744
TERMINATED NA

Study of PET Scans and Serotonin in Hot Flashes Treatment

NCT00249847
TERMINATED Phase 2

Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma

NCT00248534
COMPLETED Phase 2

Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00276588
COMPLETED Phase 2

Lomustine in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00293280
COMPLETED Phase 2

Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia

NCT00133991
COMPLETED Phase 2

Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer

NCT00281866
COMPLETED

Risk Factors for Developing a Blood Clot in Patients Who Are Undergoing Cancer Treatment for Newly Diagnosed Gliomas

NCT00253669
TERMINATED Phase 2

Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery

NCT00493025
TERMINATED Phase 2

Temozolomide During and After Radiation Therapy in Treating Patients Who Have Undergone Previous Surgery and Placement of Gliadel Wafers for Newly Diagnosed Glioblastoma Multiforme

NCT00238277
COMPLETED Phase 1

Study of Image-guided Dosimetry for Interstitial Prostate Brachytherapy

NCT00426959
COMPLETED NA

Broccoli Sprout Extract in Preventing Lung Cancer in Smokers

NCT00255775
COMPLETED Phase 2

Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma

NCT00278161
COMPLETED Phase 2

Sirolimus in Treating Patients With Advanced Pancreatic Cancer

NCT00499486
COMPLETED Phase 1

Sirolimus in Treating Patients With Metastatic or Unresectable Solid Tumors

NCT00368914
COMPLETED Phase 1

Study of Docetaxel +153 Sm-EDTMP in Patients With Hormone-Refractory Prostate Cancer

NCT00559429
COMPLETED Phase 2

Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma

NCT00258206
← Previous Page 9 of 11 Next →

Phase Distribution

PhaseTrial count
Phase 1 185
Phase 2 210
Phase 3 5

Therapeutic Areas

Prostate Cancer 17
Pancreatic Cancer 14
Breast Cancer 11
Brain and Central Nervous System Tumors 6
Bladder Cancer 6
Lung Cancer 5
Adenocarcinoma of the Prostate 4
Leukemia 4
Colorectal Cancer 4
Head and Neck Cancer 4

What is open in the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins pipeline

69 recruiting of 523 indexed (13% open); 301 completed (58%).

Phase mix: 5 late (III/IV) vs 395 early (I/II) (early-phase heavy).

Top condition: Prostate Cancer (17 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: open-pipeline peers nationwide

Peers matched on 523 registered trials and 13% open enrollment, not the therapeutic-area sidebar.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600 0%5%10%15%20%25% Total trials Recruiting share Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAbbVieBoehringer IngelheimGilead SciencesH. Lee Moffitt Cancer Center and Research InstituteMetroHealth Medical CenterTexas Tech University Health Sciences CenterChiesi Farmaceutici S.p.A.Dizal Pharmaceuticals
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 523 trials (± recruiting share)

Sponsors near 13% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins page

523 registered trials is a research-attention snapshot, not an endorsement of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins or any single study.

  • 69 of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Prostate Cancer is the condition Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins pipeline card: 523 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.